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ABSTRACT
Although the mobilization of peripheral blood stem cells from normal donors using granulocyte colony-
stimulating factor is widely used, the ideal method for the administration of filgrastim has not been determined.
Therefore, we compared the efficacy of peripheral blood stem cell mobilization on day 4 of filgrastim between
once-daily (group O) and twice-daily (group T) administration of filgrastim at 400 g/m2/d. In all, 38 and 34
donors were randomly assigned to groups O and T, respectively. The number of CD34 cells collected on day
4 was not significantly different (1.74  106 cells/kg in group O and 2.08  106 cells/kg in group T, P  .37).
The incidence and severity of adverse events were similar in the two groups. The baseline white blood cell
count was the strongest predictor of poor mobilization. Donor age, sex, and serum concentrations of several
cytokines did not significantly affect the CD34 cell yield. In conclusion, once-daily administration of filgras-
tim at 400 g/m2/d appeared to be appropriate for the mobilization of CD34 cells in normal donors when
apheresis is planned on day 4 of filgrastim. Selection of a donor with a steady-state white blood cell count of
5.0  109/L or more may lead to a lower incidence of poor mobilization.
© 2006 American Society for Blood and Marrow Transplantation
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Peripheral blood stem cell (PBSC) graft is widely
sed for both autologous and allogeneic transplanta-
ion and produces faster neutrophil recovery than
one marrow (BM) cells [1]. A recent meta-analysis
howed that allogeneic PBSC transplantation is asso-
iated with a decreased relapse rate and better survival
n patients with late-stage hematologic malignancies t
08ompared with allogeneic BM transplantation, al-
hough it is also associated with a higher incidence of
xtensive chronic graft-versus-host disease [2]. As for
onors, PBSC and BM donors experienced similar
evels of discomfort, but the symptoms were resolved
ooner in PBSC donors [3].
Granulocyte colony-stimulating factor (G-CSF) is
he most widely used cytokine for PBSC mobilization.
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Filgrastim Dosage for PBSC Mobilization
Bowever, the ideal method for PBSC mobilization
as not been determined. A dose-response relation-
hip between G-CSF and the number of collected
D34 cells has been shown in healthy donors and
atients with cancer [4-7]. The European Group for
lood and Marrow Transplantation recommended the
dministration of G-CSF at 10 g/kg/d for healthy
BSC donors [8]. Although most centers administer
-CSF once daily, others recommended the admin-
stration of G-CSF in two divided doses at a 12-hour
nterval [9,10]. In a retrospective study by Kröger
t al. [10], more CD34 cells were collected with
wice-daily (2  5 g/kg/d) ﬁlgrastim than with once-
aily (1  10 g/kg/d) ﬁlgrastim. On the other hand,
nderlini et al. [11] showed that there was no differ-
nce in the efﬁcacy of PBSC mobilization between the
wo methods. The only prospective randomized con-
rolled trial showed that twice-daily administration
as superior to once-daily administration in mobiliz-
ng CD34 cells on day 5 of G-CSF administration
12]. However, it is a common practice to start
pheresis on day 4 to reduce the cost of G-CSF.
herefore, in this multicenter, open-labeled, random-
zed controlled trial, we intended to compare the ef-
cacy of PBSC mobilization on day 4 of ﬁlgrastim, the
requency and severity of adverse events, and medical
osts between once-daily and twice-daily administra-
ion of ﬁlgrastim. In addition, we prospectively eval-
ated the impact of potential confounding factors on
D34 cell yield, including serum levels of several
ytokines.
ONORS AND METHOD
onor Selection
Healthy PBSC donors aged 16 to 65 years were
nrolled in this study. Donors with any organ dysfunc-
ion were excluded. This protocol was approved by
ach institutional review board and written informed
onsent was obtained from each donor.
ssignment, Mobilization, and Apheresis
Donors were randomly assigned to receive ﬁlgras-
im either at 400 g/m2 once daily (group O) or at 200
g/m2 twice daily (group T). Assignment was strati-
ed by the institute. Donors were hospitalized before
lgrastim administration. Subcutaneous injection of
lgrastim was started in the evening for group O, and
n the morning for group T, to make the interval from
he last ﬁlgrastim administration to the beginning of
pheresis similar in both groups. The ﬁrst apheresis
as performed on the morning of day 4. When the
umber of collected CD34 cells per recipient body
eight did not reach the target for each recipient, ﬁl-
rastim was administered in the evening and apheresis
as repeated on the next day. Apheresis was performed t
B&MTsing a continuous-ﬂow cell separator (COBE Spectra,
ambro BCT, Lakewood, USA). A total blood vol-
me of 150 to 200 mL/kg was processed per apheresis
t a ﬂow rate of 60 to 80 mL/min.
onitoring of Adverse Events
Physical examination, and subjective and objective
ndings were recorded at entry, every day from the
tart to the end of ﬁlgrastim administration, and at a
ollow-up a few weeks later. The severity of pain was
ecorded twice daily by the donors using the visual
nalog scale during ﬁlgrastim administration [13].
he severity of adverse events was recorded according
o the National Cancer Institute-Common Toxicity
riteria version 2.0. For the treatment of bone pain
aused by ﬁlgrastim, oral acetaminophen at 400 mg,
ith at least a 4-hour interval, was prescribed.
tatistical Analysis
The primary end point was the number of CD34
ells per donor body weight collected on day 4. Sec-
ndary end points included bone pain, the dose of
cetaminophen, platelet counts immediately after the
rst apheresis, and medical costs. Poor mobilizers
ere deﬁned as those with a collection of less than
.0  106 CD34 cells per donor body weight on day
. We planned to include 40 donors, 20 in each group,
ecause 37 and 17 donors in each group were required
o detect a difference in the number of CD34 cells
f 1  106/kg and 1.5  106/kg, respectively, with a
-tailed alpha error of 5% and a beta error of 20%.
he target number of included patients was increased
o 72 patients at an interim analysis. Continuous vari-
bles were analyzed with Student t test or the Mann-
hitney U test and dichotomous variables were ana-
yzed with Fisher exact test.
ESULTS
onors and Assignments
Between April 2001 and May 2002, a total of 72
ealthy donors from 4 institutes were enrolled into
his study. In all, 38 and 34 donors were assigned to
he groups O and T, respectively. Filgrastim was not
dministered in one donor of group O because of the
ecipient’s condition, and this donor was excluded from
he analysis. The two groups were equivalent with regard
o sex (P  .64), age (P  .12), body weight (P  .70),
nd white blood cell (WBC) (P  .35) and platelet
P  .44) counts. Group O included 22 male and 15
emale members with a median age of 43 years (range
7-62). Group T included 18 men and 16 women with
median age of 51 years (range 19-65). The mean
ody weight of the donors was 60.1 kg (SD 10.7) in
roup O and 59.2 kg (SD 8.7) in group T, respec-
ively. The mean WBC and platelet counts were 6.2
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409/L (SD 1.4) and 253  109/L (SD 56) in group O
nd 5.9  109/L (SD 1.1) and 243  109/L (S.D. 47)
n group T, respectively.
Two donors in group O were erroneously given
lgrastim at 200 g/m2 twice daily (protocol viola-
ion). These donors were included in group O in the
ntention-to-treat (ITT) analysis, but were included in
roup T in the per-protocol (PP) analysis. All of the
onors completed a 3-day administration of ﬁlgrastim
ithout any dose adjustment. Apheresis was per-
ormed once, twice, and three times in 27, 28, and 16
onors, respectively.
D34 Cell Yield
As shown in Figure 1, the CD34 cell yields per
onor body weight on day 4 ﬁt a log normal distribu-
ion. Therefore, the statistical analyses for the CD34
ell yields were performed after a logarithmic trans-
ormation. The number of CD34 cells collected on
ay 4 was not signiﬁcantly different in both ITT and
P analyses (Table 1). The geometric mean value was
.74 106 cells/kg in group O and 2.08 106 cells/kg
n group T (P  .37) in the ITT analysis and 1.77 
06 cells/kg in group O and 2.02  106 cells/kg in
igure 1. Number of CD34 cells per donor body weight (kg)
ollected on day 4 of G-CSF administration before (A) and after (B)
ogarithmic transformation. A
10roup T (P  .51) in the PP analysis. A post hoc
ower analysis revealed that this study had the statis-
ical power to detect a difference in the number of
D34 cells of 1.1  106/kg, with a 2-tailed alpha
rror of 5% and a beta error of 20%. Therefore, the
ack of a signiﬁcant difference between the two groups
as not a result of a lack of adequate statistical power.
In the ITT analyses, there were 21 and 16 poor
obilizers among the 37 patients of group O and 34
f group T, respectively (57% versus 47%, P  .48).
n the PP analyses, there were 19 and 18 poor mobi-
izers among the 35 patients of group O and 36 of
roup T, respectively (54% versus 50%, P  .81).
dverse Events and Medical Cost Analyses
Adverse events and medical costs were evaluated
ith PP analyses (Table 2). The area under the curve
f the visual analog scale from day 1 to 4 was higher in
roup T, but this difference was not statistically sig-
iﬁcant (P  .15). The mean total dose of acetamin-
phen prescribed from day 1 to 4 was equivalent in the
able 1. Number of CD34 Cells Collected on Day 4 of Granulocyte
olony-Stimulating Factor Administration
ntent to Treat
No. of Subjects Group O 37 Group T 34 Total 71
D34 cell yield (106/kg donor body weight)
Geometric mean 1.74 2.08
95% CI 1.30–2.32 1.57–2.76 P  .37
er Protocol
No. of Subjects Group O 35 Group T 36 Total 71
D34 cell yield (106/kg donor body weight)
Geometric mean 1.77 2.02
95% CI 1.30–2.40 1.55–2.65 P  .51
I indicates conﬁdence interval.
able 2. Comparison of Adverse Events and Medical Costs Based on
er-Protocol Analysis
No. of Subjects Group O 35 Group T 36 Total 71
UC of VAS (mm  ds)
Median 21.5 51
Range 0.0–195.5 0.0–230.0 P  .15
otal dose of acetaminophen (mg)
Mean 729 783
SD 916 900 P  .80
ostapheresis platelet count on day 4 (109/L)
Mean 124 114
SD 160 146 P  .33
uration of hospitalization
Median 6 6
Range 5–10 3–15 P  .87
edical costs (¥)
Mean 495,509 501,795
SD 138,320 149,870 P  .85UC indicates area under the curve; VAS, visual analog scale.
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Bwo groups (729 versus 783 mg, P  .80). The mean
latelet count after the ﬁrst apheresis was also similar
n the two groups (12.4  104/L versus 11.4 
04/L, P  .33). However, the platelet count after
pheresis showed a signiﬁcant negative correlation
ith donor age (P  .03). The median duration of
ospitalization was 6 days in both groups (P  .87).
he mean medical costs were 495,509 ¥ and 501,795 ¥
n groups O and T, respectively (P  .85).
isk Factors for Poor Mobilization
We evaluated the impact of potential confounding
actors on the CD34 cell yield (Table 3). Among the
actors before mobilization, only the baseline WBC
ount was signiﬁcantly different between the good
nd poor mobilizers (6.4  109/L versus 5.7  109/L,
 .02). As shown in Figure 2, there were no good
obilizers among donors with a baseline WBC count
ess than 5.0  109/L. Neither age nor sex signiﬁ-
antly affected the CD34 cell yield (Figure 3). There
ere no difference in baseline serum concentrations of
arious cytokines between the two groups.
There was also no signiﬁcant difference in the
eak serum concentration of G-CSF (P  .94). As for
actors on day 4, just before the ﬁrst apheresis, both
he WBC count and CD34 cells in the peripheral
able 3. Characteristics of 71 Patients Grouped According to the Outco
G
actors before mobilization
Age (y)
Sex (male/female)
Donor BW (kg)
Group (O/T)
WBC at entry (109/L)
Platelet at entry (109/L)
G-CSF (fmol/L)
TPO (fmol/L)
IL-3 (fmol/L)
SCF (fmol/L)
FLT-3L (fmol/L)
EPO (fmol/L)
actors on day 1 of G-CSF administration
G-CSF C4 (pg/mL)
actors on day 4 of G-CSF administration
WBC on day 4 (109/L)
Platelet on day 4 (109/L)
CD34 on day 4 (109/L)
Apheresis volume (L)
xpression on the cell surface of harvested cells
CD11a (%)
CD49d (%)
CD62L (%)
W indicates body weight; C4, plasma concentration 4 h after
granulocyte colony-stimulating factor; IL-3, interleukin-three; S
(per-protocol analysis); WBC, white blood cell.
oor mobilizers were deﬁned as those with a collection of 2.0
administration. Numbers and those in parentheses show meanlood signiﬁcantly correlated with the incidence of t
B&MToor mobilization (P  .0005 and P  .0004, respec-
ively). There was no difference in the expression of
D11a, CD49d, and CD62L on collected CD34
ells between good and poor mobilizers (P  .58, P 
76, and P  .55, respectively).
ISCUSSION
This randomized controlled trial demonstrated
hat once-daily administration of ﬁlgrastim at 400
g/m2 is as effective as twice-daily administration in
wo divided doses for the mobilization of CD34 cells
n healthy donors. This result is different from that in
he study by Kröger et al. [12], which showed that
ore CD34 cells were obtained by twice-daily ad-
inistration than by once-daily administration (5.4 
06 cells/kg versus 4.0  106 cells/kg, P  .007). The
ajor difference between these two studies is the
iming of apheresis. We evaluated the CD34 cell
ield on day 4 of G-CSF administration, whereas
röger et al. [12] performed their evaluation on day 5.
nderlini et al. [14] demonstrated in a sequentially
omparative study that a single apheresis on day 5
ielded signiﬁcantly more CD34 cells than that on
ay 4 (P  .01). However, it may still be reasonable to
tart apheresis on day 4 considering the cost of ﬁlgras-
obilization
obilizers Poor Mobilizers P Value
(12.7) 45.5 (14.4) .18
/13 19/18 .47
(9.1) 58.7 (10.4) .42
/18 19/18 .81
(1.2) 5.7 (1.2) .02
(52) 247 (52) .80
(543) 553 (436) .87
(1459) 5034 (3918) .59
(131) 215 (907) .27
(6402) 46,214 (8231) .38
(2613) 6005 (2335) .41
(868) 3290 (1854) .21
(28477) 45,920 (25364) .94
(9.6) 37.8 (9.3) .0005
(51) 210 (48) .71
(0.063) 0.016 (0.012) .0004
(1.87) 10.2 (1.3) .10
(7.9) 16.3 (6.6) .58
(7.0) 17.3 (4.4) .76
(3.2) 7.8 (3.5) .55
istration; EPO, erythropoietin; FLT-3L, Flt-3 ligand; G-CSF,
m cell factor; TPO, thrombopoietin; O, once-daily; T, twice-daily
CD34 cells per donor body weight (kg) on day 4 of G-CSF
, except for sex and group.me of M
ood M
41.1
21
60.6
16
6.4
250
527
4633
39.4
44,654
5504
2856
46,498
46.0
215
0.056
10.9
15.0
16.8
7.2
admin
CF, ste
 106im, because about 40% of the donors could ﬁnish
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4pheresis on day 4. Both the number of collected
D34 cells and the incidence of poor mobilization
n day 4 were equivalent between once-daily and
wice-daily administration of ﬁlgrastim. Therefore,
nce-daily administration is generally recommended for
BSC mobilization from healthy donors, if the initiation
f apheresis is planned on day 4. However, twice-daily
dministration may be better if a large number of
D34 cells is required, for example for haploidenti-
al transplantation using CD34 cell selection, be-
ause apheresis on day 5 would be indispensable.
Several risk factors for poor mobilization have
een retrospectively identiﬁed, including higher age
nd female sex [4,15-18]. In this study, the baseline
ow WBC count was the strongest predictor of poor
obilization. Especially, donors with a baseline WBC
ount of less than 5.0  109/L were exclusively poor
obilizers. Therefore, it may be advisable to select a
onor with a high baseline WBC count if a patient has
ore than one healthy HLA antigen–matched donor.
urprisingly, donor age and sex had no impact on the
ield of CD34 cells.
The steady-state plasma level of Flt-3 ligand showed
signiﬁcant negative correlation with CD34 cell
ield in patients undergoing high-dose chemotherapy
nd autologous stem cell rescue [19]. This may sug-
est that the plasma level of Flt-3 ligand is elevated in
atients with poor BM function, because Flt-3 ligand
nduces multilineage hematopoietic cell differentia-
ion and effectively mobilizes stem cells. Therefore, in
igure 2. Peripheral blood WBC count before mobilization grouped
ccording to outcome of mobilization. Poor mobilizers were deﬁned as
hose with collection of less than 2.0  106 CD34 cells per donor
ody weight (kg) on day 4 of ﬁlgrastim administration.his study, we evaluated the correlation between the t
12D34 cell yield and the serum levels of several he-
atopoietic cytokines including Flt-3 ligand, interleu-
in-3, stem cell factor, and G-CSF, but failed to ﬁnd
ny signiﬁcant correlations. Therefore, the measure-
ent of steady-state serum cytokine levels is not use-
ul for the prediction of poor mobilization in normal
onors. The peak serum level of G-CSF also had no
mpact on the CD34 cell yield. The expression of
dhesion molecules including L-selectin (CD62L),
LA-4 (CD49d/CD29), and LFA-1 (CD11a/CD18)
ay play an important role in stem cell mobilization
nd homing [20,21]. Therefore, we evaluated the ex-
ression of these adhesion molecules on collected
D34 cells. However, there was no difference in the
xpression levels of these molecules between good and
oor mobilizers.
There were no differences in the incidence of
dverse events between the two groups, although the
rea under the curve of visual analog scale tended to
e slightly higher for group T. One of the major
dverse events of concern is thrombocytopenia after
pheresis. In this study, a signiﬁcant negative correla-
ion was observed between donor age and platelet
ount after the ﬁrst apheresis. Although only one
onor developed thrombocytopenia with less than
0  109/L after the ﬁrst apheresis, we should care-
ully monitor the platelet count and bleeding ten-
ency, especially in elderly donors.
In conclusion, once-daily administration of ﬁlgras-
im at 400 g/m2/d appeared to be appropriate for the
obilization of CD34 cells in normal donors when
pheresis is planned on day 4 of ﬁlgrastim. Selection of
donor with a steady-state WBC count of 5.0 
09/L or more may lead to a lower incidence of poor
obilization. Although an adequate number of CD34
ells can be collected from elderly donors, the careful
onitoring of adverse events, especially the platelet
ount after apheresis, is important.
igure 3. Correlation between age and number of CD34 cells per
onor body weight (kg) collected on day 4 of G-CSF administra-
ion.
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